Esketamine

Active substance

Esketamine

Holder

Janssen-Cilag

Status

Running

Indication

ESK is intended for treatment‐resistant depression (Major Depressive Disorder in adults who have not responded to at least two different treatments with antidepressants in the current moderate to severe depressive episode). ESK must be given in combination with an SSRI or SNRI.

Public documents

Approbation

Information for the patient

Informed consent

Last update

21/09/2020

Last updated on 28/09/2022